Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
(2013) In European Journal of Cancer 49(1). p.115-120- Abstract
- Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. Methods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy.... (More)
- Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. Methods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. Results: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). Conclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival. (C) 2012 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3481061
- author
- Sorenson, Sverre ; Fohlin, Helena ; Lindgren, Andrea ; Lindskog, Magnus ; Bergman, Bengt ; Sederholm, Christer ; Ek, Lars LU ; Lamberg, Kristina and Clinchy, Birgitta
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Non-small cell lung cancer, Celecoxib, Chemotherapy, Survival, Plasma, VEGF
- in
- European Journal of Cancer
- volume
- 49
- issue
- 1
- pages
- 115 - 120
- publisher
- Elsevier
- external identifiers
-
- wos:000312896700015
- scopus:84871407592
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2012.07.032
- language
- English
- LU publication?
- yes
- id
- d8ccfc3f-d411-4edf-9178-c027644019ae (old id 3481061)
- date added to LUP
- 2016-04-01 10:49:38
- date last changed
- 2022-04-28 01:51:05
@article{d8ccfc3f-d411-4edf-9178-c027644019ae,
abstract = {{Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. Methods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. Results: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). Conclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival. (C) 2012 Elsevier Ltd. All rights reserved.}},
author = {{Sorenson, Sverre and Fohlin, Helena and Lindgren, Andrea and Lindskog, Magnus and Bergman, Bengt and Sederholm, Christer and Ek, Lars and Lamberg, Kristina and Clinchy, Birgitta}},
issn = {{1879-0852}},
keywords = {{Non-small cell lung cancer; Celecoxib; Chemotherapy; Survival; Plasma; VEGF}},
language = {{eng}},
number = {{1}},
pages = {{115--120}},
publisher = {{Elsevier}},
series = {{European Journal of Cancer}},
title = {{Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy}},
url = {{http://dx.doi.org/10.1016/j.ejca.2012.07.032}},
doi = {{10.1016/j.ejca.2012.07.032}},
volume = {{49}},
year = {{2013}},
}